Verily Life Sciences LLC

Verily Life Sciences LLC, doing business as G L S, provides wastewater surveillance testing and disease monitoring services to federal public health agencies as a prime contractor on full-and-open procurements. A for-profit limited liability company and subsidiary of Alphabet Inc., headquartered in South San Francisco, California, Verily operates primarily under NAICS 543711 (Testing Laboratories and Services) and PSC Reference Laboratory Testing, with no SBA set-aside certifications across its federal footprint.

Verily's federal work centers exclusively on wastewater pathogen surveillance for emerging and endemic infectious diseases. Representative prime awards include a $42.3 million definitive contract awarded by the CDC Pittsburgh on January 12, 2024, for wastewater surveillance testing under Executive Order 14398 with place of performance in South San Francisco and ultimate completion September 14, 2026; a $38.8 million definitive contract from CDC Pittsburgh on September 26, 2023, for wastewater testing to support COVID-19 and monkeypox response efforts with ultimate completion April 22, 2025; and a $5.6 million definitive contract from CDC Pittsburgh on November 9, 2023, for six-month wastewater surveillance testing through May 6, 2024. Most recently, on September 29, 2026, CDC Pittsburgh awarded Verily a $145 million single-award Indefinite Delivery Contract for scalable wastewater surveillance capabilities to detect routine and emerging infectious disease pathogens across multiple jurisdictions through September 27, 2031, supported by a $5.6 million delivery order under the same vehicle issued the same day with place of performance in Coppell, Texas and ultimate completion September 28, 2027. A $750 thousand definitive contract from the National Institute on Aging on September 25, 2024, for wastewater surveillance testing was terminated for convenience under the President's Department of Government Efficiency cost efficiency initiative.

Verily's customer concentration is heavily concentrated with the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh, which accounts for 5 awards and $237.3 million of combined potential value — 100% of the identified award base. Across 7 total awards tracked in the source (6 prime, 1 sub), combined potential value stands at $238 million with $51.7 million obligated to date. Activity has remained sparse but steady at two awards per year in 2023 and 2024, one award in 2025, and two awards in 2026. One award carrying $5.6 million in potential value reaches ultimate completion within the next twenty-four months. As a subcontractor, Verily performs wastewater testing for dengue virus RNA detection under a sub-award to the Association of Public Health Laboratories, Inc., a federal grant recipient under an unspecified grantor program (award date June 25, 2025).